| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEP.510290603 |
| P698 | PubMed publication ID | 10347106 |
| P2093 | author name string | Poupon R | |
| Poupon RE | |||
| Chrétien Y | |||
| Bonnand AM | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Hepatocellular carcinoma in primary biliary cirrhosis and its impact on outcomes | Q34445524 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis | Q42280172 | ||
| Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA-PBC Study Group | Q71748735 | ||
| Survival in ursodeoxycholic acid-treated patients with biliary cirrhosis | Q71832756 | ||
| A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid | Q72189521 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy | Q77058192 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| P304 | page(s) | 1668-1671 | |
| P577 | publication date | 1999-06-01 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group | |
| P478 | volume | 29 |
| Q37207972 | 38-year-old woman with abnormal liver enzymes and hyperlipidemia |
| Q44314885 | A comparison of fibrosis progression in chronic liver diseases |
| Q35490131 | A decline of LAMP- 2 predicts ursodeoxycholic acid response in primary biliary cirrhosis |
| Q44825279 | A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results |
| Q34672135 | Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis |
| Q99550841 | An update on the management of cholestatic liver diseases |
| Q36036857 | Antifibrotic therapy in chronic liver disease |
| Q90443379 | Apoptosis induced by ursodeoxycholic acid in human melanoma cells through the mitochondrial pathway |
| Q34269621 | Autoimmune liver disease. Current standards, future directions. |
| Q100416036 | Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis |
| Q46408092 | Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis |
| Q33723821 | Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. |
| Q34787714 | Bone involvement in patients with chronic cholestasis |
| Q28251174 | Chaperoning to the metabolic party: The emerging therapeutic role of heat-shock proteins in obesity and type 2 diabetes |
| Q41824260 | Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis |
| Q29615503 | Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes |
| Q33870255 | Chronic cholestatic diseases |
| Q44487597 | Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis |
| Q37317654 | Current and future anti-fibrotic therapies for chronic liver disease |
| Q34408950 | Current status of therapy in autoimmune liver disease |
| Q34687676 | Drug therapy of primary biliary diseases: classical and modern strategies. |
| Q92864604 | Emerging therapies for PBC |
| Q35552299 | Endoplasmic reticulum stress and insulin resistance post-trauma: similarities to type 2 diabetes |
| Q28577217 | Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transition |
| Q51137626 | Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study. |
| Q34917584 | Evidence that proteosome inhibitors and chemical chaperones can rescue the activity of retinol dehydrogenase 12 mutant T49M. |
| Q34769039 | Fatigue in cholestatic liver disease--a perplexing symptom |
| Q46982754 | Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom |
| Q24244255 | Glucocorticosteroids for primary biliary cirrhosis |
| Q34057526 | Hepatology in the new millennium. Advances in viral hepatitis, hepatic disorders, and liver transplantation |
| Q44139912 | Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis |
| Q85642882 | Increased cancer risk in a large population-based cohort of patients with primary biliary cirrhosis: follow-up for up to 36 years |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q40140683 | Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines |
| Q34936618 | Medical and economic impact of autoimmune hepatitis |
| Q81724957 | Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis |
| Q44277489 | Methotrexate therapy for primary biliary cirrhosis |
| Q45279435 | No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis |
| Q89538006 | Osteoporosis in Primary Biliary Cholangitis: Prevalence, Impact and Management Challenges |
| Q58311495 | Osteoporosis in Primary Biliary Cirrhosis: A Randomized Trial of the Efficacy and Feasibility of Estrogen/Progestin |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q34316236 | Pregnancy in primary biliary cirrhosis complicated by portal hypertension: report of a case and review of the literature |
| Q42365884 | Preliminary structure-activity relationship on theonellasterol, a new chemotype of FXR antagonist, from the marine sponge Theonella swinhoei |
| Q39047912 | Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics |
| Q26781780 | Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective |
| Q54390436 | Primary biliary cholangitis: new treatments for an old disease. |
| Q56428273 | Primary biliary cirrhosis |
| Q56854243 | Primary biliary cirrhosis |
| Q84230884 | Primary biliary cirrhosis |
| Q21202919 | Primary biliary cirrhosis |
| Q38058979 | Primary biliary cirrhosis and bile acids |
| Q26853145 | Primary biliary cirrhosis and liver transplantation |
| Q26992087 | Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis |
| Q26799419 | Primary biliary cirrhosis: From bench to bedside |
| Q44736205 | Primary biliary liver cirrhosis and overlap syndrome. Diagnosis and therapy |
| Q64101976 | Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells |
| Q36518882 | Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score |
| Q44004769 | Quantitative testing of liver function compared to prognostic scores in patients with primary biliary cirrhosis |
| Q46966926 | Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids |
| Q35030826 | Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? |
| Q45074381 | Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment |
| Q34170449 | The cell and molecular biology of hepatic fibrogenesis. Clinical and therapeutic implications |
| Q37021448 | The unfolded protein response in hereditary haemochromatosis |
| Q39816216 | Therapeutic Equivalence of Ursodeoxycholic Acid Tablets and Ursodeoxycholic Acid Capsules for the Treatment of Primary Biliary Cirrhosis |
| Q34398020 | Treatment of primary biliary cirrhosis |
| Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
| Q43623767 | Ursodeoxycholic acid for primary biliary cirrhosis: lessons from the past--issues for the future |
| Q33866782 | Ursodeoxycholic acid treatment of vanishing bile duct syndromes |
Search more.